VPC
Vestal Point Capital Portfolio holdings
AUM
$2.73B
1-Year Est. Return
128.57%
This Fund
S&P 500
1 Year Est. Return
+128.57%
AUM
$2.73B
AUM Growth
+$522M
(+24%)
Holding
105
Top Buys
| 1 | +$134M | |
| 2 | +$118M | |
| 3 | +$104M | |
| 4 |
ABVX
Abivax
ABVX
|
+$98.2M |
| 5 |
Merck
MRK
|
+$72.7M |
Top Sells
| 1 | +$104M | |
| 2 | +$87.8M | |
| 3 | +$76.8M | |
| 4 |
Ionis Pharmaceuticals
IONS
|
+$70.3M |
| 5 |
Becton Dickinson
BDX
|
+$60.8M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
RAPP
26
Rapport Therapeutics
RAPP
$1.33B
| $33.7M | 1.24% |
1,110,000
+160,000
|
|
||
27
Solid Biosciences
SLDB
$570M
| $32.8M | 1.2% |
5,815,000
+2,840,000
|
|
||
28
Celldex Therapeutics
CLDX
$1.96B
| $31.6M | 1.16% |
1,165,000
-40,000
|
|
||
29
Scholar Rock
SRRK
$4.6B
| $30.8M | 1.13% |
700,000
-800,000
|
|
||
30
KalVista Pharmaceuticals
KALV
$856M
| $30.5M | 1.12% |
1,890,000
+1,140,000
|
|
||
31
Vera Therapeutics
VERA
$2.85B
| $27.9M | 1.02% |
550,000
-210,000
|
|
||
32
Xenon Pharmaceuticals
XENE
$4.59B
| $26.9M | 0.99% |
600,000
-500,000
|
|
||
33
Lantheus
LNTH
$5.14B
| $24M | 0.88% |
360,000
+190,000
|
|
||
34
Revolution Medicines
RVMD
$18.8B
| $23.5M | 0.86% |
295,000
-335,000
|
|
||
35
Zymeworks
ZYME
$1.7B
| $22.8M | 0.84% |
865,000
-900,000
|
|
||
36
Immunocore
IMCR
$1.56B
| $20.3M | 0.74% |
+585,000
|
|
||
|
UPB
37
Upstream Bio Inc
UPB
$499M
| $19.5M | 0.72% |
+720,000
|
|
||
|
BBNX
38
Beta Bionics
BBNX
$461M
| $18.3M | 0.67% |
600,000
|
|
||
|
CBIO
39
Crescent Biopharma
CBIO
$340M
| $17.8M | 0.65% |
+1,500,000
|
|
||
40
BioCryst Pharmaceuticals
BCRX
$2.06B
| $17.6M | 0.64% |
+2,250,000
|
|
||
41
Penumbra
PEN
$13.2B
| $15.5M | 0.57% |
+50,000
|
|
||
42
Geron
GERN
$1.01B
| $14.9M | 0.55% |
11,320,000
-5,905,000
|
|
||
43
Repligen
RGEN
$6.43B
| $13.6M | 0.5% |
83,000
-317,000
|
|
||
44
Zimmer Biomet
ZBH
$18.2B
| $13.5M | 0.49% |
+150,000
|
|
||
45
Bristol-Myers Squibb
BMY
$120B
| $13.5M | 0.49% |
+250,000
|
|
||
46
Monte Rosa Therapeutics
GLUE
$1.22B
| $12.2M | 0.45% |
775,000
-25,000
|
|
||
47
Fulcrum Therapeutics
FULC
$509M
| $10.7M | 0.39% |
+950,000
|
|
||
48
Savara
SVRA
$1.07B
| $9.68M | 0.36% |
1,606,000
-2,409,000
|
|
||
49
enGene Holdings
ENGN
$480M
| $9.53M | 0.35% |
1,055,000
+685,000
|
|
||
50
Agios Pharmaceuticals
AGIO
$1.63B
| $8.85M | 0.32% |
325,000
+198,000
|
|